Sutro Biopharma, Inc.
STRO· Nasdaq
Released Aug 8, 2022, after the close
10-Q filed Aug 8, 2022, 39 days after period end · 0000950170-22-015584
| Metric | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|---|
| Revenue | $28.10M | $28.05M | $9.47M | $10.53M |
| Net Income | -$26.01M | -$6.15M | $29.87M | -$13.79M |
| EPS Diluted |
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR
| -$0.55 |
| -$0.13 |
| $0.94 |
| -$0.60 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.